FDA approved oral, once-daily, non-statin medicines on August 26, 2025.
3 reports, 1 independent
Updated Aug 26
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved oral, once-daily, non-statin medicines on August 26, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Settlement agreement restricts generic market due to FDA approval of oral non-statin medicines, leading to ongoing patent litigation against Renata Limited.Sub-event
FDA approved new oral, once-daily, non-statin medicines.1 source
Keep exploring
The entities involved
- FDA
-
Esperion Therapeutics
American pharmaceutical company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireEsperion to Participate in Upcoming September Investor Conferences ANN ARBOR, Mich., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating i
- GlobeNewswireEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Compa
- GlobeNewswireEsperion to Report Second Quarter 2025 Financial Results on August 5 ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 fin